Claims
- 1. An isolated polynucleotide selected from the group consisting of:
(a) an isolated polynucleotide encoding a human G-protein coupled receptor, or functional fragment thereof, comprising the amino acid sequence as set forth in SEQ ID NO:2; (b) An isolated composition comprising the polynucleotide according to (a). (c) An isolated polynucleotide comprising SEQ ID NO:1; (d) An isolated polynucleotide having the nucleic acid sequence of ATCC Accession No. PTA-2966; (e) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 4 to 1524 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon; (f) An isolated polynucleotide having the nucleic acid sequence according to nucleotides 1 to 1524 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon; (g) A polynucleotide which is fully complementary to the polynucleotide according to (a) thru (f); and (h) A hybridization probe comprising the polynucleotide according to (a) thru (g).
- 2. An expression vector containing the polynucleotide according to claim 1.
- 3. A host cell containing the expression vector according to claim 2.
- 4. A substantially purified G-protein coupled receptor polypeptide selected from the group consisting of:
(a) A substantially purified G-protein coupled receptor polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2. (b) The polypeptide according to (a), wherein the amino acid sequence differs from SEQ ID NO:2 only by conservative substitutions; (c) An isolated and substantially purified G-protein coupled receptor polypeptide encoded by the nucleic acid sequence of ATCC Accession No. PTA-2966; (d) An isolated polypeptide having the amino acid sequence according to amino acids 2 to 508 of SEQ ID NO:2, wherein said amino acid encode a polypeptide of SEQ ID NO:2 minus the start methionine; (e) An isolated polypeptide having the amino acid sequence according to amino acids 1 to 508 of SEQ ID NO:2, wherein said amino acid encode a polypeptide of SEQ ID NO:2 including the start methionine; (f) A substantially purified fragment of the G-protein coupled receptor polypeptide according to any one of (a) to (e).
- 5. A substantially purified fusion protein comprising an amino acid sequence as set forth in SEQ ID NO:2 and an amino acid sequence of an Fc portion of a human immunoglobulin protein.
- 6. A pharmaceutical composition comprising the polypeptide, or a functional fragment thereof, according to claim 1, and a pharmaceutically acceptable diluent or excipient.
- 7. A purified antibody which binds specifically to the polypeptide according to claim 4, or an antigenic epitope thereof.
- 8. A method of screening a library of molecules or compounds with a polynucleotide to identify at least one molecule or compound therein which specifically binds to the polynucleotide sequence, comprising:
(a) combining the polynucleotide according to claim 1, with a library of molecules or compounds under conditions to allow specific binding; and (b) detecting specific binding, thereby identifying a molecule or compound, which specifically binds to a G-protein coupled receptor-encoding polynucleotide sequence.
- 9. The method according to claim 8, wherein the candidate compounds are small molecules, therapeutics, biological agents, or drugs.
- 10. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:
(a) contacting a test compound with a cell or tissue expressing the polypeptide according to claim 4; and (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 11. A method of treating a neurological disorder in a mammal comprising administration of the G-protein coupled receptor polypeptide or homologue according to any one of claims 1, 4, or, 5 in an amount effective to treat the neurological disorder.
- 12. A substantially purified G-protein coupled receptor polypeptide consisting of an amino acid sequence as set forth in SEQ ID NO:2.
- 13. The polypeptide according to claim 12, wherein the amino acid sequence differs from SEQ ID NO:2 only by conservative substitutions.
- 14. An isolated and purified polynucleotide encoding a human G-protein coupled receptor, or functional fragment thereof, consisting of the amino acid sequence as set forth in SEQ ID NO:2.
- 15. A method of treating a disease, disorder, or condition related to the brain comprising administering the G-protein coupled receptor polypeptide or homologue according to claim 12 or 13 in an amount effective to treat the brain-related disorder.
- 16. The polypeptide of claim 12 or 13, further comprising the polypeptide expressed in the caudate nucleus, substantia nigra, thalamus, amygdala, hippocampus, cerebellum, and corpus collosum.
- 17. A cell comprising NFAT/CRE and the polypeptide of claim 12 or 13.
- 18. A cell comprising NFAT G alpha 15 and the polypeptide of claim 12 or 13.
- 19. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:
(a) contacting a test compound with a cell or tissue expressing the polypeptide according to claim 12 or 13; and (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 20. The method according to claim 19, wherein the candidate compounds are agonists or antagonists of G-protein coupled receptor activity.
- 21. The method according to claim 20, wherein the polypeptide activity is associated with the brain.
- 22. The method according to claim 20, wherein the candidate modulating compounds are peptides.
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Serial No. 60/248,285, filed Nov. 14, 2000; to provisional application U.S. Serial No. 60/268,581, filed Feb. 14, 2001; to provisional application U.S. Serial No. 60/308,285, filed Jul. 27, 2001; and to provisional application U.S. Serial No. 60/317,166, filed Sep. 4, 2001.
Provisional Applications (4)
|
Number |
Date |
Country |
|
60248285 |
Nov 2000 |
US |
|
60268581 |
Feb 2001 |
US |
|
60308285 |
Jul 2001 |
US |
|
60317166 |
Sep 2001 |
US |